NCT06238583No Longer Available不适用
Copanlisib Expanded Access Program (EAP) for Patients Who, in the Opinion of Their Healthcare Provider, Are Deriving Benefit From Copanlisib Therapy
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- Bayer
- 试验地点
- 1
研究概览
简要总结
The purpose of this Expanded Access Program (EAP) is to allow patients to continue receiving treatment with copanlisib if they are currently having, in the opinion of their healthcare provider, an objective favorable response when taking copanlisib. Patients considering this access program should have no other therapeutic option, have not developed a disease and/or medical condition (including pregnancy), and/or have a toxicity that would conflict with continuing to receive copanlisib.
研究设计
- 研究类型
- Expanded Access
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient has provided written informed consent.
- •Patient meets one of the following criteria:
- •Already enrolled and on treatment with copanlisib in Bayer-sponsored Study 17067 (CHRONOS-3), OR
- •Already enrolled and on treatment with copanlisib in an investigator-initiated research (IIR)/institution-sponsored collaborative study (ISCS), OR
- •Currently on copanlisib treatment prescribed by a healthcare provider.
- •Patient is deriving an objective favorable response from copanlisib in the opinion of their healthcare provider.
- •Patient has no suitable alternative treatments available.
- •Women of childbearing potential and men must agree to use effective contraception when sexually active due to potential embryo-fetal toxicity for 1 month after the last dose.
排除标准
- •Patients who may have developed a disease/condition/toxicity that would conflict with continuing to receive copanlisib treatment.
- •Patients on treatment with rituximab (R) either alone or in combination with chemotherapy, including an alkylating agent (e.g. bendamustine [R-B] or cyclophosphamide, hydroxydoxorubicin, vincristine, prednisone [R-CHOP]) for relapsed indolent non-Hodgkin's lymphoma (iNHL).
研究者
研究点 (1)
Loading locations...
相似试验
Approved For Marketing
不适用
Cenobamate Expanded Access Program (EAP)Partial EpilepsyNCT04513860SK Life Science, Inc.
Available
不适用
Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's DiseaseNon-healing WoundThromboangiitis ObliteransNCT04914247Actelion
No Longer Available
不适用
Expanded Access to EpcoritamabLymphomaNCT05692050AbbVie
No Longer Available
不适用
Expanded Access to ElezanumabAcute Spinal Cord Injury (SCI)NCT04278235AbbVie
Available
不适用
Expanded Access to UpadacitinibSpondyloarthritisAxial SpondyloarthritisNon-radiographic AxialNon Segmental VitiligoHidradenitis SuppurativaCrohn DiseaseUlcerative ColitisAtopic DermatitisRheumatoid ArthritisPsoriatic ArthritisGiant Cell ArteritisSystemic Lupus ErythematosusAlopecia AreataNCT04159597AbbVie